Clear all search history
Law & Crime
Disasters & Accidents
War & Conflict
Hospitality & Recreation
Rituxan articles over last 30 days
articles last 30 days
articles per day
Mentioned in this news
$250 Billion in Biotech Drug Savings on Brink of ...
At least 14 expensive biotechnology medicines that have never before faced generic rivals in the U.S. are being targeted by drugmakers who want to sell imitations at cheaper prices, according to...
Read more at
Food and Drug Administration
Doctor affiliated with local business investigated
An oncologist who has begun treating patients in Great Bend has come under scrutiny, triggered by a complaint to the Kansas Board of Healing Arts from a Reno County patient, according to a one-year...
Read more at Great Bend Tribune
St. Rose Ambulatory & Surgery Center
OpportunityAnalyzer: Graft-Versus-Host Disease - ...
New Drugs to Boost Graft-Versus-Host Disease Treatment Market by 2018. The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at...
Read more at Business Wire
Roche Investors Should Breathe Easier After Inter...
Before this deal, there was nothing extraordinary about Roche's respiratory business. Roche has thrived mainly on its strength in cancer treatments. While the company's oncology position remains...
Read more at
+ 329 more articles
When To Invest In Protein Production The Risk-Rew...
A message to biotech start-ups, scientist-entrepreneurs and life sciences organizations banking on your exciting protein-based drug-discovery programs and technologies: When it comes to the timing of...
Read more at PharmaceuticalOnline
As biotech startups try to master 'plantibodies,'...
LOS ANGELES (Reuters) - Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with...
Read more at
Ireland Business World
+ 1 more articles
Roche Holding AG
U.S. Food and Drug Administration
Latest from Twitter
Parts of this website powered by Open Calais, a toolkit for rich semantic metadata extraction.
Interceder is a topic search engine aggregating the latest news on any topic into a single window of information. This page has been automatically generated. To contact Interceder
Your privacy is important. Interceder does not collect and keep any personal information about visitors to the site. Interceder may use third-party advertising companies to serve ads. These companies may use information (not including your name, address, email address, or telephone number) about your visits to this and other websites in order to provide advertisements on this website, other websites, and other forms of media about goods and services of interest to you.